Our study also considered TOP2A as a key biomarker for the development and progression of HCC, as supported by previous studies [12, 14, 15, 18, 20–25, 27, 32–36, 39, 41–43, 45, 46, 48, 50, 51, 54–59]. This evidence concerns the gene TOP2A and hepatocellular carcinoma.